Electroacupuncture for Control of Myeloablative Chemotherapy–Induced Emesis

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
High-dose, multiple-day, multiple-drug myeloablative chemotherapy poses substantial challenges to emesis control. The combination of chemotherapy agents is highly emetogenic; most patients have experienced emesis with multiple courses of prior chemotherapy; and patients may have received other medical care or medications and adjuncts that can contribute to emesis. During the last 2 decades, new effective antiemetic pharmacological agents have helped to improve control of chemotherapy-induced emesis. Because of concerns about pharmacokinetic interaction between high-dose chemotherapy agents and the new antiemetic medications, some patients receiving intense multiple-agent, myeloablative chemotherapy regimens might not be able to use these newer antiemetics concurrently.1-3 This constellation of factors makes the management of emesis difficult.